The CCDC25 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted cell population designed to ablate expression of the CCDC25 protein. This polyclonal knockout model is generated in the HeLa cervical adenocarcinoma cell line and provides a mixed population of edited cells, enabling robust functional studies without clonal selection artifacts. The loss of CCDC25 disrupts its role as a receptor for neutrophil extracellular traps (NETs), serving as a valuable tool for investigating NET-driven signaling in cancer biology.
HeLa cells, originally derived from a human cervical adenocarcinoma, are HPV18-positive and represent a widely used epithelial cancer model. Their aggressive and invasive phenotype, coupled with well-characterized signaling networks, makes them particularly suited for studying mechanisms of cell migration and metastasis. The epithelial origin and HPV-driven transformation background of HeLa cells provide a relevant context for examining CCDC25-dependent pathways implicated in tumor progression.
CCDC25 functions as a cell-surface receptor for NETs, translating extracellular NET signals into intracellular migratory responses. Upon NET binding, CCDC25 engages the integrin-linked kinase (ILK)?C??-parvin?CRAC1 signaling cascade, leading to actin cytoskeleton reorganization and enhanced cell motility. This pathway is further modulated by upstream regulators such as TGF-??, which can amplify CCDC25 responsiveness. The direct interaction between CCDC25 and ILK positions CCDC25 as a critical node connecting extracellular NETosis cues to the actin polymerization machinery, ultimately driving invasion and metastasis.
In the HeLa context, CCDC25 knockout cells provide a loss-of-function platform to dissect the molecular underpinnings of NET-induced metastasis. Given the established roles of CCDC25 in hepatocellular carcinoma, colorectal cancer, and breast cancer, this polyclonal model extends the translational relevance of HeLa cells to pan-cancer migration studies. By removing CCDC25, researchers can interrogate the dependency of the ILK?C??-parvin?CRAC1 pathway on NET signals and assess compensatory mechanisms or upstream regulators like TGF-?? in a clean genetic background.
Typical research applications include Transwell migration and invasion assays to quantify motility changes, co-immunoprecipitation to probe CCDC25?CILK complex formation, and phospho-ILK analysis to monitor pathway activation. The polyclonal nature of this population permits bulk assays such as Western blotting, RT-qPCR, and RNA-seq for transcriptomic profiling, while flow cytometry enables analysis of cell surface marker expression. Immunofluorescence microscopy can visualize actin dynamics downstream of NET stimulation. These cells are compatible with NETosis studies and cancer metastasis research, offering a versatile system for validating therapeutic targets within the CCDC25 axis. For further details and ordering information, please contact Ascent Research.
